The U.S. Food and Drug Administration is using federal tax dollars to create a demand for human body parts from aborted babies by signing a contract to acquire “fresh” fetal tissue to transplant into “humanized mice.”
The further implication, points out CNSNews.com, is that the FDA has an interest in the continuation of legalized abortions at a stage of pregnancy in which the body parts can be retrieved.
Citing information published by the FDA and the General Services Administration, CNSNews.com said the ultimate objective of the new $15,900 contract, signed July 25, is to help create laboratory mice that will have a functioning “human immune system.”
The Congressional Research Service confirmed that the “fetal tissue used in research is obtained from elective abortions.”
The House Energy and Commerce Committee’s Select Investigative Panel on Infant Lives was presented in 2016 with with a background paper from Harvard University explaining that mice with human immune systems “are engineered to this condition only by means of the use of human fetal material” and that this material can only come from aborted babies not from miscarriages.
In 2015, an independent undercover investigation produced a series of videos that captured abortion-industry executives on camera admitting their engagement in the sale of the body parts of aborted babies. The revelations prompted congressional inquiries and a Justice Department investigation. House Republicans formed a select investigative panel that spent 15 months examining the issue and issued a 471-page report but no charges.
FDA committed to ‘highest ethical standards’
The FDA confirmed of CNSNews.com that the federal government signed the contract, but the agency refused to answer 17 other questions, offering instead a three-paragraph statement.
One of the questions the FDA refused to answer was the “total number of babies expected to donate their tissue to the FDA to create humanized mice during the year-long duration of the contract.” CNSNews.com also asked whether or not the mothers were made aware that the body parts were being used for such research.
The FDA, in its statement, emphasized it was committed to making certain its research followed “all legal requirements” and met “the highest ethical standards.”
“At the FDA, research involving human fetal tissue accounts for a very small fraction of the FDA’s total research and has been used in situations where it is critical to understanding how the human immune system responds to certain drugs and biologics,” the statement said. “This work has led to a better understanding of a number of conditions and diseases that affect millions of Americans.”
The agency said its researchers “obtain fetal tissue from a non-profit Tissue Procurement Organization (TPO) that have [sic] provided assurances that they are in compliance with all applicable legal requirements, including relevant provisions relating to research involving human fetal tissue.”
“FDA is not involved in the TPO’s sourcing of the tissue,” it said.
Since 2012, according to the GSA’s Federal Procurement Data System, the FDA has signed eight contracts with ABR, including the one signed July 25, CNSNews.com said.
Seven of the contracts expressly cite “Humanized Mice,” “Human Fetal Tissue” or “Tissue Procurement for Humanized Mice” in the contract’s “description of requirement.” The eighth simply says: “Human Tissue.”
